Initial reports documenting HGF-mediated resistance to BRAF inhibition in BRAF mutant melanoma identified correlations between HGF expression levels and patient response to BRAF and/or MEK inhibitor therapy. This evidence concerns the gene MAP2K7 and melanoma.